Janux Therapeutics Inc (NASDAQ:JANX)’s traded shares stood at 0.78 million during the last session, with the company’s beta value hitting 3.16. At the close of trading, the stock’s price was $39.37, to imply a decrease of -3.22% or -$1.31 in intraday trading. The JANX share’s 52-week high remains $71.71, putting it -82.14% down since that peak but still an impressive 80.16% since price per share fell to its 52-week low of $7.81. The company has a valuation of $2.28B, with an average of 0.93 million shares in intraday trading volume over the past 10 days and average of 1.17 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Janux Therapeutics Inc (JANX), translating to a mean rating of 1.27. Of 3 analyst(s) looking at the stock, 0 analyst(s) give JANX a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.45.
Janux Therapeutics Inc (NASDAQ:JANX) trade information
After registering a -3.22% downside in the last session, Janux Therapeutics Inc (JANX) has traded red over the past five days. The 5-day price performance for the stock is -9.45%, and -31.90% over 30 days. With these gigs, the year-to-date price performance is -26.47%. Short interest in Janux Therapeutics Inc (NASDAQ:JANX) saw shorts transact 8.55 million shares and set a 8.41 days time to cover.
The extremes give us $42 and $100 for target low and target high price respectively. As such, JANX has been trading -154.0% off suggested target high and -6.68% from its likely low.
Janux Therapeutics Inc (JANX) estimates and forecasts
The rating firms project that company’s revenue will grow 36.46% compared to the previous financial year.
Revenue forecast for the current quarter as set by 10 analysts is 490k. Meanwhile, for the current quarter, a total of 9 analyst(s) estimate revenue growth to 1.21M.Earnings reports from the last fiscal year show that sales brought in 2.46M and 1.25M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -80.09% before dropping -3.29% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -92.62% for the past 5-year period. While 2025 is set for a -11.44% return in earnings, projections for the next 5 years are at -24.84% annually.
JANX Dividends
Janux Therapeutics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Janux Therapeutics Inc (NASDAQ:JANX)’s Major holders
Janux Therapeutics Inc insiders hold 7.22% of total outstanding shares, with institutional holders owning 87.11% of the shares at 93.90% float percentage. In total, 87.11% institutions holds shares in the company, led by RA CAPITAL MANAGEMENT, L.P.. As of 2024-06-30, the company held over 9.17 million shares (or 18.6864% of shares), all amounting to roughly $383.95 million.
The next major institution holding the largest number of shares is FMR LLC with 7.78 million shares, or about 15.8566% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $325.8 million.
We also have Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Janux Therapeutics Inc (JANX) shares. Going by data provided on Nov 30, 2024 , Fidelity Growth Company Fund holds roughly 1.31 shares. This is just over 2.50% of the total shares, with a market valuation of $51.59 million. Data from the same date shows that the other fund manager holds a little less at 1.0, or 1.91% of the shares, all valued at about 39.44 million.
